Unlock stock picks and a broker-level newsfeed that powers Wall Street.

NasdaqGM - Nasdaq Real Time Price USD

Aerovate Therapeutics, Inc. (AVTE)

2.4900

-0.0200

(-0.80%)

At close: April 4 at 4:00:02 PM EDT

2.4900

0.00

(0.00%)

After hours: April 4 at 4:46:38 PM EDT

Jade, another biotech spinout of Paragon, to merge with Aerovate

The immune disease drug developer expects to raise $300 million in a private financing set to close before its combination with the struggling Aerovate.

BioPharma Dive 5 months ago

AVTE
-0.80%
Aerovate Therapeutics and Jade Biosciences Announce Merger Agreement

Merger to create a company focused on advancing Jade Biosciences’ portfolio of novel therapies that aim to redefine the standard of care for patients with autoimmune diseases Jade Biosciences, the fourth company founded on assets licensed from Paragon Therapeutics, expects to initiate a clinical trial for JADE-001 in the second half of 2025 Approximately $300 million raised to date, including anticipated proceeds from an oversubscribed pre-closing private financing, expected to fund operations t

GlobeNewswire 5 months ago

AVTE
-0.80%
Aerovate Therapeutics to Explore Strategic Alternatives

WALTHAM, Mass., July 08, 2024 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), which previously announced it was halting enrollment and shutting down the Phase 3 portion of the Inhaled iMatinib Pulmonary Arterial Hypertension Clinical Trial (IMPAHCT) as well as the long-term extension study, today announced that it will conduct a comprehensive review of strategic alternatives focused on maximizing shareholder value. As part of this review process, Aerovate has engaged Wedbush PacG

GlobeNewswire 8 months ago

AVTE
-0.80%
Ligand to buy Apeiron; Roche reports another TIGIT setback

Acquiring Apeiron will hand Ligand royalty rights on the neuroblastoma drug Qarziba. Elsewhere, CSL reported the first commercial treatment of patients in Europe with its gene therapy Hemgenix.

BioPharma Dive 8 months ago

ROG.SW

LGNZZ

AVTE
-0.80%
Aerovate slashes workforce after failed Phase IIb trial

The company has announced plans to lay off 39 employees, with most of the workforce cuts expected in coming months.

Clinical Trials Arena 8 months ago

AVTE
-0.80%
The 3 Hottest Stock Downgrades From Last Week

Wall Street’s leading analysts have been adjusting their S&P 500 forecasts in recent days. Driven by potential Federal Reserve interest rate cuts, strong performance from large technology companies and solid corporate earnings growth, analysts expect the S&P 500 to consolidate its gains above 5500. According to LSEG data, collective S&P 500 profits are expected to increase by approximately 10.7% from the previous year to $495.7 billion, surpassing the 8% growth seen in the first quarter. Evercor

InvestorPlace 9 months ago

PLTR

AAPL

^GSPC
Aerovate (AVTE) Down as Lead Drug Fails to Meet PAH Study Goals

Aerovate's (AVTE) shares plunge 93% as its lead candidate, AV-101, fails to meet the primary and secondary endpoints in the phase IIb/III study to treat pulmonary arterial hypertension patients.

Zacks 9 months ago

AVTE
-0.80%
ALXO
Why 93% Of Aerovate Therapeutics' Value Just Went Up In Smoke

Aerovate Therapeutics said Monday its experimental blood pressure medicine failed in Phase 2 testing, and the biotech stock plummeted 93%.

Investor's Business Daily 9 months ago

AVTE
-0.80%
Top Midday Decliners

Top Midday Decliners

PREMIUM
MT Newswires 9 months ago

AVTE
-0.80%
OVID
Aerovate Therapeutics Announces 24-Week Topline Results from the Phase 2b Portion of IMPAHCT Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension

AV-101 did not meet the primary endpoint of change in pulmonary vascular resistance (PVR) for any of the studied dosesWALTHAM, Mass., June 17, 2024 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE) today announced topline results from the Phase 2b portion of the Inhaled iMatinib Pulmonary Arterial Hypertension Clinical Trial (IMPAHCT), a Phase 2b/Phase 3, randomized, double-blind, placebo-controlled, multi-national trial of AV-101, a novel dry powder inhaled formulation of imatinib,

GlobeNewswire 9 months ago

AVTE
-0.80%
Here's Why We're Watching Aerovate Therapeutics' (NASDAQ:AVTE) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

Simply Wall St. 9 months ago

AVTE
-0.80%
Aerovate Therapeutics Presents Baseline Data from the Phase 2b Portion of the IMPAHCT Trial at the American Thoracic Society 2024 International Conference

Baseline characteristics reflect a PAH population with significant disease Topline data from Phase 2b portion of IMPAHCT study to be released in June 2024 Enrollment into the Phase 3 portion of IMPAHCT continues at more than 120 sites globally WALTHAM, Mass., May 21, 2024 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease, today pre

GlobeNewswire 10 months ago

AVTE
-0.80%
Aerovate Therapeutics Announces First Quarter Financial Results and Business Highlights

Topline data expected in June 2024 from Phase 2b portion of the IMPAHCT global Phase 2b/Phase 3 clinical trial of AV-101 for pulmonary arterial hypertension (PAH) Enrollment continues into the Phase 3 portion of the IMPAHCT trial of AV-101 Poster to be presented with baseline characteristics of the Phase 2b portion of the IMPAHCT trial at the ATS 2024 Conference on May 21 Cash runway into 2026, based on our current operating plan WALTHAM, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Aerovate Therapeu

GlobeNewswire 10 months ago

AVTE
-0.80%

Performance Overview

Return	AVTE	S&P 500 (^GSPC)
YTD	-6.04%	-13.73%
1-Year	-91.44%	-1.42%
3-Year	-84.59%	+10.72%